Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)
Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Topics & Concepts
MedicineHazard ratioInternal medicineBladder cancerGemcitabineChemotherapyNeoadjuvant therapyProportional hazards modelOncologyConfidence intervalVinblastineCisplatinSurgeryCancerUrologyBreast cancerBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentUrinary Bladder and Prostate Research